ArticleJournal of cheminformatics2026
PepGraphormer: an ESM-GAT hybrid deep learning framework for antimicrobial peptide prediction.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NeuroPred-GMC: a dual-branch deep learning architecture for neuropeptide prediction based on gated dilated convolutional network and multi-scale convolutional network.Journal of computer-aided molecular design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The prediction of Antimicrobial Peptides (AMPs) is a critical research area in drug discovery. Traditional methods, which rely on sequence alignment or handcrafted features, often fail to capture complex sequence-function relationships. Recently, Large Language Models (LLMs) like ESM2 have demonstrated remarkable success in extracting deep semantic features from protein sequences. Meanwhile, Graph Neural Networks (GNNs), particularly Graph Attention Networks (GATs), can effectively learn inter-node relationships, specifically capturing peptide-residue compositional links and inter-residue co-occurrence patterns, to aggregate neighborhood information. In this work, we propose PepGraphormer, a novel fusion model that combines the powers of large-scale pretraining from ESM2 and the structural learning advantages from GATs for AMP prediction. We first construct a heterogeneous graph with peptide sequences and amino acids as nodes, where ESM2 is leveraged to generate high-quality initial embeddings for the peptide sequence nodes. Then the classification fuses the direct predictions from ESM2 and the graph-based predictions from the GAT. The training jointly trains the ESM2 and GAT modules and learns the embeddings for nodes in the graph. Comparisons with current state-of-the-art models on multiple datasets demonstrate that PepGraphormer achieves excellent accuracy and stability in the AMP prediction task. Further ablation and generalization experiments confirm the effectiveness and robustness of this fusion framework, presenting a new avenue for computationally-driven therapeutic peptide discovery.Scientific contribution This work proposes a novel framework PepGraphormer that combines the powers of transformer-based large language model (ESM2) and graph attention network for antimicrobial peptide prediction, without requiring the 3D protein structural information used in previous studies. The model significantly outperforms state-of-the-art methods and various deep learning baselines on multiple AMP benchmark datasets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.